Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 2, 2009, Pages 294-298

  Oh, Jung Hwan ^b   Dong, Mi Sook ^a   Choi, Myung Gyu ^b   Yoo, Hae Won ^a   Lee, Sang Bum ^a   Park, Young In ^a   Chung, In Sik ^b  

^a Korea University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

CYP2C19; Gene; Genetic polymorphism; Helicobacter pylori; Multidrug resistance; Pantoprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; PANTOPRAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

EID: 58849097707     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05605.x     Document Type: Article

References (23)

1. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000 118 : S2 8.
2. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract. Res. Clin. Gastroenterol. 2007 21 : 315 24.
3. Labenz J, Stolte M, Blum AL et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995 37 : 39 43.
4. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. 2000 38 : 243 70.
5. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999 13 : 27 36.
6. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol. Drug Interact. 1997 14 : 55 82.
7. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 2005 20 : 153 67.
8. Higgins CF. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992 8 : 67 113.
9. Pauli-Magnus C, Rekersbrink S, Klots U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 2001 364 : 551 7.
10. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001 69 : 169 74.
11. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur. J. Clin. Pharmacol. 2005 61 : 375 9.
12. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996 272 : 210 8.
13. Furuta T, Ohashi K, Kamata T et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 1998 129 : 1027 30.
14. Furuta T, Shirai N, Takashima M et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001 11 : 341 8.
15. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig. Liver Dis. 2001 33 : 671 5.
16. Ishizaki T, Sohn DR, Kobayashi K et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. 1994 16 : 214 15.
17. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996 60 : 661 6.
18. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. 2004 76 : 201 9.
19. Sapone A, Vaira D, Trespidi S et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am. J. Gastroenterol. 2003 98 : 1010 15.
20. Oh JH, Choi MG, Dong MS et al. Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. J. Gastroenterol. Hepatol. 2007 22 : 1429 34.
21. Furuta T, Sugimoto M, Shirai N et al. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther. 2007 26 : 693 703.
22. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 2003 17 : 99 109.
23. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am. J. Gastroenterol. 2005 100 : 1696 701.